Suvorexant regulatory update

FDA approved Belsomra suvorexant from Merck to treat insomnia. The pharma said it plans to launch the dual orexin receptor antagonist in the U.S. by late 2014 or early 2015. The launch is contingent on final scheduling by the U.S. Drug Enforcement Agency. In February, the DEA proposed to classify Belsomra as a class IV controlled substance, where class I indicates the highest potential for abuse and class V the lowest. ...